ABSTRACT

INTRODUCTION

Tobacco-related oropharyngeal cancer (SCCA) has been increasing at a rapid rate. This study describes the outcomes of Transoral Robotic Surgery (TORS) for primary oropharyngeal and laryngopharyngeal lesions in 64 patients. The mean TORS set up time in the current series is ±6 min, which is concordant with the range of that reported in the literature, ranging from 9 to 68 min. The average hospital length of stay (LOS) was 2.71 ±1.58 days. There was a trend toward longer TORS setup time in the first 10 cases, which decreased in the subsequent 54 cases. In the present series, 5 out of the 34 (15%) HPV positive patients eventually required gastrostomy tube placement due to dysphagia after initiation of adjuvant RT or CRT. The last follow up visit of 42% of patients demonstrated a DFS of 91% with 83% of patients tolerating an oral diet. Because HPV+ are common in the oropharynx and have been recognized as a separate form of head and neck cancer, clinicians are actively studying this population to identify the optimal treatment strategies for HPV+ patients. The objectives of this study are to report on the feasibility, safety, utility of the procedure, as well as functional and long term outcomes. These are the primary results from the largest prospective study of patients undergoing TORS.

METHODS AND MATERIALS

A SBM-approved study was performed at the Ohio State University, Office of Research Practices. Patients undergoing TORS were identified from the Ohio State University Medical Center Transoral Robotic Surgery database. TORS was performed utilizing a da Vinci Xi surgical system (Intuitive Surgical, CA) with the patient in the supine position. The surgical team included a primary surgeon, assistant surgeon, and scrub nurse. Twenty-five patients received the neoadjuvant chemotherapy regimen of cisplatin (50 mg/m²) and concurrent intensity modulated radiotherapy (IMRT) with 70 Gy in 28 fractions over 6 weeks. The remaining patients received surgery-only treatment. Post operatively, patients were followed by the TORS surgical team.

RESULTS

CONCLUSIONS

DISCUSSION

REFERENCES

Outcomes of Transoral Robotic Surgery: A Preliminary Clinical Experience

Agnieszka Hurtuk MD, Amit Agrawal MD, Matthew Old MD, Neeru T Teknos MD, Enver Ozer MD

Department of Otolaryngology—Head and Neck Surgery, Comprehensive Cancer Center - Arthur James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University Medical Center, Columbus, Ohio, USA.

ABSTRACT

INTRODUCTION

Oropharyngeal cancer (SCCA) has been increasing at a rapid rate. This study describes the outcomes of Transoral Robotic Surgery (TORS) for primary oropharyngeal and laryngopharyngeal lesions in 64 patients. The mean TORS set up time in the current series is ±6 min, which is concordant with the range of that reported in the literature, ranging from 9 to 68 min. The average hospital length of stay (LOS) was 2.71 ±1.58 days. There was a trend toward longer TORS setup time in the first 10 cases, which decreased in the subsequent 54 cases. In the present series, 5 out of the 34 (15%) HPV positive patients eventually required gastrostomy tube placement due to dysphagia after initiation of adjuvant RT or CRT. The last follow up visit of 42% of patients demonstrated a DFS of 91% with 83% of patients tolerating an oral diet. Because HPV+ are common in the oropharynx and have been recognized as a separate form of head and neck cancer, clinicians are actively studying this population to identify the optimal treatment strategies for HPV+ patients. The objectives of this study are to report on the feasibility, safety, utility of the procedure, as well as functional and long term outcomes. These are the primary results from the largest prospective study of patients undergoing TORS.

METHODS AND MATERIALS

A SBM-approved study was performed at the Ohio State University, Office of Research Practices. Patients undergoing TORS were identified from the Ohio State University Medical Center Transoral Robotic Surgery database. TORS was performed utilizing a da Vinci Xi surgical system (Intuitive Surgical, CA) with the patient in the supine position. The surgical team included a primary surgeon, assistant surgeon, and scrub nurse. Twenty-five patients received the neoadjuvant chemotherapy regimen of cisplatin (50 mg/m²) and concurrent intensity modulated radiotherapy (IMRT) with 70 Gy in 28 fractions over 6 weeks. The remaining patients received surgery-only treatment. Post operatively, patients were followed by the TORS surgical team.

RESULTS

CONCLUSIONS

DISCUSSION

REFERENCES

Outcomes of Transoral Robotic Surgery: A Preliminary Clinical Experience

Agnieszka Hurtuk MD, Amit Agrawal MD, Matthew Old MD, Neeru T Teknos MD, Enver Ozer MD

Department of Otolaryngology—Head and Neck Surgery, Comprehensive Cancer Center - Arthur James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University Medical Center, Columbus, Ohio, USA.

ABSTRACT

INTRODUCTION

Oropharyngeal cancer (SCCA) has been increasing at a rapid rate. This study describes the outcomes of Transoral Robotic Surgery (TORS) for primary oropharyngeal and laryngopharyngeal lesions in 64 patients. The mean TORS set up time in the current series is ±6 min, which is concordant with the range of that reported in the literature, ranging from 9 to 68 min. The average hospital length of stay (LOS) was 2.71 ±1.58 days. There was a trend toward longer TORS setup time in the first 10 cases, which decreased in the subsequent 54 cases. In the present series, 5 out of the 34 (15%) HPV positive patients eventually required gastrostomy tube placement due to dysphagia after initiation of adjuvant RT or CRT. The last follow up visit of 42% of patients demonstrated a DFS of 91% with 83% of patients tolerating an oral diet. Because HPV+ are common in the oropharynx and have been recognized as a separate form of head and neck cancer, clinicians are actively studying this population to identify the optimal treatment strategies for HPV+ patients. The objectives of this study are to report on the feasibility, safety, utility of the procedure, as well as functional and long term outcomes. These are the primary results from the largest prospective study of patients undergoing TORS.

METHODS AND MATERIALS

A SBM-approved study was performed at the Ohio State University, Office of Research Practices. Patients undergoing TORS were identified from the Ohio State University Medical Center Transoral Robotic Surgery database. TORS was performed utilizing a da Vinci Xi surgical system (Intuitive Surgical, CA) with the patient in the supine position. The surgical team included a primary surgeon, assistant surgeon, and scrub nurse. Twenty-five patients received the neoadjuvant chemotherapy regimen of cisplatin (50 mg/m²) and concurrent intensity modulated radiotherapy (IMRT) with 70 Gy in 28 fractions over 6 weeks. The remaining patients received surgery-only treatment. Post operatively, patients were followed by the TORS surgical team.

RESULTS

CONCLUSIONS

DISCUSSION

REFERENCES

Outcomes of Transoral Robotic Surgery: A Preliminary Clinical Experience

Agnieszka Hurtuk MD, Amit Agrawal MD, Matthew Old MD, Neeru T Teknos MD, Enver Ozer MD

Department of Otolaryngology—Head and Neck Surgery, Comprehensive Cancer Center - Arthur James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University Medical Center, Columbus, Ohio, USA.

ABSTRACT

INTRODUCTION

Oropharyngeal cancer (SCCA) has been increasing at a rapid rate. This study describes the outcomes of Transoral Robotic Surgery (TORS) for primary oropharyngeal and laryngopharyngeal lesions in 64 patients. The mean TORS set up time in the current series is ±6 min, which is concordant with the range of that reported in the literature, ranging from 9 to 68 min. The average hospital length of stay (LOS) was 2.71 ±1.58 days. There was a trend toward longer TORS setup time in the first 10 cases, which decreased in the subsequent 54 cases. In the present series, 5 out of the 34 (15%) HPV positive patients eventually required gastrostomy tube placement due to dysphagia after initiation of adjuvant RT or CRT. The last follow up visit of 42% of patients demonstrated a DFS of 91% with 83% of patients tolerating an oral diet. Because HPV+ are common in the oropharynx and have been recognized as a separate form of head and neck cancer, clinicians are actively studying this population to identify the optimal treatment strategies for HPV+ patients. The objectives of this study are to report on the feasibility, safety, utility of the procedure, as well as functional and long term outcomes. These are the primary results from the largest prospective study of patients undergoing TORS.